BWX Technologies shares surge 5.08% intraday on progress in medical isotopes and U.S. Navy contract wins.

BWX Technologies surged 5.08% intraday following its presentation at the CJS Securities 26th Annual Investor Conference on January 14, 2026. The company highlighted progress toward FDA approval of its Technetium-99m generator, a critical diagnostic imaging tool, which could bolster domestic supply security and expand its medical isotopes business. This development reinforced investor confidence in BWX’s long-term growth narrative, particularly in radiopharmaceuticals, while reaffirming 2025 revenue guidance above $3.1 billion. The announcement aligned with broader optimism around BWX’s dual focus on defense contracts and medical innovation, driving immediate intraday buying momentum.